ANN TAYLOR

General issues related to corporate tax reform, including the deduction of interest,general issues related to the 40% excise tax on employer-sponsored health care; and all provisions of HR1270 and S709 "Restoring Access to Medication Act of 2015".

General issues related to corporate tax reform, including the deduction of interest, an extension of bonus depreciation, a delay of the medical device tax, and a strengthened, permanent U.S. R&D tax credit, including all provisions of HR880 "American Research and Competitiveness Act of 2015"; and proposed amendment #2 to the Senate amendment to HR 2029, Rules Committee Print 114-40, showing the text of "Protecting Americans from Tax Hikes Act of 2015"; general issues related to the 40% excise tax on employer-sponsored health care, including all provisions of S2045 and HR2050 "Middle Class Health Benefits Tax Repeal Act", all provisions of HR879 "Ax the Tax on Middle Class Americans' Health Plans Act", and proposed amendment #1 to the Senate amendment to HR2029, Rules Committee Print 114-39, showing the text of the "Consolidated Appropriations Act, 2016"; and all provisions of HR1270 and S709 "Restoring Access to Medication Act of 2015".

Corporate tax reform; a strengthened and permanent U.S. R&D tax credit, including all provisions of HR880 "American Research and Competitiveness Act of 2015"; and all provisions of HR1270 and S709 "Restoring Access to Medication Act of 2015"

Issues related to corporate tax reform, including the deduction of interest, the Orphan drug tax credit, and a strengthened and permanent U.S. R&D tax credit, and all provisions of HR880 "American Research and Competitiveness Act of 2015"; and all provisions of HR1270 and S709 "Restoring Access to Medication Act of 2015"

Issues related to corporate tax reform, including the deduction of interest, the Orphan drug tax credit, and a strengthened and permanent U.S. R&D tax credit, and all provisions of HR880 "American Research and Competitiveness Act of 2015"; and all provisions of HR1270 and S709 "Restoring Access to Medication Act of 2015"

Issues related to corporate tax reform, including the deduction of interest and a strengthened and permanent U.S. R&D tax credit, and all provisions of HR880 "American Research and Competitiveness Act of 2015"; all provisions of HR1270 and S709 "Restoring Access to Medication Act of 2015"; general issues related to the 40% excise tax on employer-sponsored health care, including all provisions of S2045 and HR2050 "Middle Class Health Benefits Tax Repeal Act" and all provisions of HR879 "Ax the Tax on Middle Class Americans' Health Plans Act"

General issues related to Trade Promotion Authority (TPA) including all such provisions of S995 and HR1890 "Bipartisan Congressional Trade Priorities and Accountability Act of 2015" and HR1314 "Ensuring Tax Exempt Organizations the Right to Appeal Act (or Trade Act of 2015)" and such portions of those bills as included in HR 2146 Defending Public Safety Employees Retirement Act and general issues related to the Trans-Pacific Partnership (TPP) and Transatlantic Trade and Investment Partnership (TTIP) negotiations.

General issues related to Trade Promotion Authority (TPA) including all such provisions of S995 and HR1890 "Bipartisan Congressional Trade Priorities and Accountability Act of 2015" and HR1314 "Ensuring Tax Exempt Organizations the Right to Appeal Act (or Trade Act of 2015)" and such portions of those bills as included in HR 2146 Defending Public Safety Employees Retirement Act and general issues related to the Trans-Pacific Partnership (TPP) and Transatlantic Trade and Investment Partnership (TTIP) negotiations.

General issues related to Trade Promotion Authority (TPA) including all such provisions of S995 and HR1890 "Bipartisan Congressional Trade Priorities and Accountability Act of 2015" and HR1314 "Ensuring Tax Exempt Organizations the Right to Appeal Act (or Trade Act of 2015)" and such portions of those bills as included in HR 2146 Defending Public Safety Employees Retirement Act and general issues related to the Trans-Pacific Partnership (TPP) and Transatlantic Trade and Investment Partnership (TTIP) negotiations.

General issues related to Trade Promotion Authority (TPA) including all such provisions of S995 and HR1890 "Bipartisan Congressional Trade Priorities and Accountability Act of 2015" and HR1314 "Ensuring Tax Exempt Organizations the Right to Appeal Act (or Trade Act of 2015)" and such portions of those bills as included in HR 2146 Defending Public Safety Employees Retirement Act and general issues related to the Trans-Pacific Partnership (TPP) and Transatlantic Trade and Investment Partnership (TTIP) negotiations.

General issues related to Trade Promotion Authority (TPA) including all such provisions of S995 and HR1890 "Bipartisan Congressional Trade Priorities and Accountability Act of 2015" and HR1314 "Ensuring Tax Exempt Organizations the Right to Appeal Act (or Trade Act of 2015)" and such portions of those bills as included in HR 2146 Defending Public Safety Employees Retirement Act and general issues related to the Trans-Pacific Partnership (TPP) and Transatlantic Trade and Investment Partnership (TTIP) negotiations.

General issues related to Trade Promotion Authority (TPA) including all such provisions of S995 and HR1890 "Bipartisan Congressional Trade Priorities and Accountability Act of 2015" and HR1314 "Ensuring Tax Exempt Organizations the Right to Appeal Act (or Trade Act of 2015)" and such portions of those bills as included in HR 2146 Defending Public Safety Employees Retirement Act and general issues related to the Trans-Pacific Partnership (TPP) and Transatlantic Trade and Investment Partnership (TTIP) negotiations.

Issues related to the Medicaid rebate policy; general issues related to the Medicare Part D program; coverage and reimbursement for the Medicare Part D prescription drug benefit and all provisions of S31 "Medicare Prescription Drug Price Negotiation Act"; general issues related to the Medicare Part B reimbursement of prescription drugs; proposals set forth in the President's Budget Request relating to applying a Medicaid rebate to Medicare Part D for low income subsidy beneficiaries, increasing the manufacturer Part D coverage gap discounts for brand name drugs, repealing the non-interference provision, restructuring generic and brand copayments for low income subsidy beneficiaries, and reducing reimbursement for Medicare Part B medicines; and all provisions of HR2 "Medicare Access and CHIP Reauthorization Act of 2015"

Issues related to the Medicaid rebate policy; general issues related to the Mediare Part D Program; coverage and reimbursement for the Medicare Part D prescription drug benefit and all provisions of S31 "Medicare Prescription Drug Price Negotiation Act"; proposals set forth in the President's Budget Request related to restructuring copayments for generic and brand drugs for low income beneficiaries; reducing reimbursement for Medicare Part B medicines; all provisions of HR2 "Medicare Access and CHIP Reauthorization Act of 2015"; all provisions of HR2005 and S1083 "Medicare Drug Savings Act of 2015" and general issues related to chronic care reform in the Medicare program.

Issues related to the Medicaid rebate policy; general issues related to the Mediare Part D Program; coverage and reimbursement for the Medicare Part D prescription drug benefit and all provisions of S31 "Medicare Prescription Drug Price Negotiation Act"; proposals set forth in the President's Budget Request related to restructuring copayments for generic and brand drugs for low income beneficiaries; reducing reimbursement for Medicare Part B medicines; all provisions of HR2 "Medicare Access and CHIP Reauthorization Act of 2015"; all provisions of HR2005 and S1083 "Medicare Drug Savings Act of 2015" and general issues related to chronic care reform in the Medicare program.

Issues related to the Medicaid rebate policy; general issues related to the Mediare Part D Program; coverage and reimbursement for the Medicare Part D prescription drug benefit and all provisions of S31 "Medicare Prescription Drug Price Negotiation Act"; proposals set forth in the President's Budget Request related to restructuring copayments for generic and brand drugs for low income beneficiaries; reducing reimbursement for Medicare Part B medicines; all provisions of HR2 "Medicare Access and CHIP Reauthorization Act of 2015"; all provisions of HR2005 and S1083 "Medicare Drug Savings Act of 2015" and general issues related to chronic care reform in the Medicare program.

Issues related to the Medicaid rebate policy; general issues related to the Mediare Part D Program; coverage and reimbursement for the Medicare Part D prescription drug benefit and all provisions of S31 "Medicare Prescription Drug Price Negotiation Act"; proposals set forth in the President's Budget Request related to restructuring copayments for generic and brand drugs for low income beneficiaries; reducing reimbursement for Medicare Part B medicines; all provisions of HR2 "Medicare Access and CHIP Reauthorization Act of 2015"; all provisions of HR2005 and S1083 "Medicare Drug Savings Act of 2015" and general issues related to chronic care reform in the Medicare program.

General issues related to corporate tax reform, including the deduction of interest, an extension of bonus depreciation, a delay of the medical device tax, and a strengthened, permanent U.S. R&D tax credit, including all provisions of HR880 "American Research and Competitiveness Act of 2015"; and proposed amendment #2 to the Senate amendment to HR 2029, Rules Committee Print 114-40, showing the text of "Protecting Americans from Tax Hikes Act of 2015"; general issues related to the 40% excise tax on employer-sponsored health care, including all provisions of S2045 and HR2050 "Middle Class Health Benefits Tax Repeal Act", all provisions of HR879 "Ax the Tax on Middle Class Americans' Health Plans Act", and proposed amendment #1 to the Senate amendment to HR2029, Rules Committee Print 114-39, showing the text of the "Consolidated Appropriations Act, 2016"; and all provisions of HR1270 and S709 "Restoring Access to Medication Act of 2015".

Issues related to corporate tax reform, including the deduction of interest and a strengthened and permanent U.S. R&D tax credit, and all provisions of HR880 "American Research and Competitiveness Act of 2015"; all provisions of HR1270 and S709 "Restoring Access to Medication Act of 2015"; general issues related to the 40% excise tax on employer-sponsored health care, including all provisions of S2045 and HR2050 "Middle Class Health Benefits Tax Repeal Act" and all provisions of HR879 "Ax the Tax on Middle Class Americans' Health Plans Act"

General issues related to corporate tax reform, including the deduction of interest, an extension of bonus depreciation, a delay of the medical device tax, and a strengthened, permanent U.S. R&D tax credit, including all provisions of HR880 "American Research and Competitiveness Act of 2015"; and proposed amendment #2 to the Senate amendment to HR 2029, Rules Committee Print 114-40, showing the text of "Protecting Americans from Tax Hikes Act of 2015"; general issues related to the 40% excise tax on employer-sponsored health care, including all provisions of S2045 and HR2050 "Middle Class Health Benefits Tax Repeal Act", all provisions of HR879 "Ax the Tax on Middle Class Americans' Health Plans Act", and proposed amendment #1 to the Senate amendment to HR2029, Rules Committee Print 114-39, showing the text of the "Consolidated Appropriations Act, 2016"; and all provisions of HR1270 and S709 "Restoring Access to Medication Act of 2015".

General issues related to Trade Promotion Authority (TPA) including all such provisions of S995 and HR1890 "Bipartisan Congressional Trade Priorities and Accountability Act of 2015" and HR1314 "Ensuring Tax Exempt Organizations the Right to Appeal Act (or Trade Act of 2015)" and such portions of those bills as included in HR 2146 Defending Public Safety Employees Retirement Act and general issues related to the Trans-Pacific Partnership (TPP) and Transatlantic Trade and Investment Partnership (TTIP) negotiations.

General issues related to Trade Promotion Authority (TPA) including all such provisions of S995 and HR1890 "Bipartisan Congressional Trade Priorities and Accountability Act of 2015" and HR1314 "Ensuring Tax Exempt Organizations the Right to Appeal Act (or Trade Act of 2015)" and such portions of those bills as included in HR 2146 Defending Public Safety Employees Retirement Act and general issues related to the Trans-Pacific Partnership (TPP) and Transatlantic Trade and Investment Partnership (TTIP) negotiations.

General issues related to Trade Promotion Authority (TPA) including all such provisions of S995 and HR1890 "Bipartisan Congressional Trade Priorities and Accountability Act of 2015" and HR1314 "Ensuring Tax Exempt Organizations the Right to Appeal Act (or Trade Act of 2015)" and such portions of those bills as included in HR 2146 Defending Public Safety Employees Retirement Act and general issues related to the Trans-Pacific Partnership (TPP) and Transatlantic Trade and Investment Partnership (TTIP) negotiations.

Education and awareness of the 2015-2016 influenza season; education and awareness of pandemic and biodefense funding; education and awareness of Dengue; general issues related to FDA and NIH funding; all issues related to the Innovations for Healthier Americans Initiative and the 21st Century Cures Initiative including all provisions of HR6 "To accelerate the discovery, development, and delivery of 21st century cures, and for other purposes (21st Century Cures Act)"; all provisions of Preserving Access to Orphan Drugs Act (discussion draft), HR3678 "Preserving Access to Orphan Drugs Act" and HR3618 "Orphan Drug Fairness Act"; education and awareness of diabetes and related treatments; education about our new cholesterol lowering drug and policy issues related to cardiovascular disease; issues related to barriers to the export of domestically manufactured vaccines; general issues related to the value of prescription medicines; general issues related to the importation of prescription drugs including all progvisions of S122 "Safe and Affordable Drugs from Canada Act of 2015"; issues related to the Over The Counter (OTC) Monograph reform; and general issues related to access to adult vaccines.

Education and awareness of the 2015-2016 influenza season; education and awareness of pandemic and biodefense funding; education and awareness of Dengue; general issues related to FDA and NIH funding; all issues related to the Innovations for Healthier Americans Initiative and the 21st Century Cures Initiative including all provisions of HR6 "To accelerate the discovery, development, and delivery of 21st century cures, and for other purposes (21st Century Cures Act)"; all provisions of Preserving Access to Orphan Drugs Act (discussion draft), HR3678 "Preserving Access to Orphan Drugs Act" and HR3618 "Orphan Drug Fairness Act"; education and awareness of diabetes and related treatments; education about our new cholesterol lowering drug and policy issues related to cardiovascular disease; issues related to barriers to the export of domestically manufactured vaccines; general issues related to the value of prescription medicines; general issues related to the importation of prescription drugs including all progvisions of S122 "Safe and Affordable Drugs from Canada Act of 2015"; issues related to the Over The Counter (OTC) Monograph reform; and general issues related to access to adult vaccines.

Education and awareness of the 2015-2016 influenza season; education and awareness of pandemic and biodefense funding; education and awareness of Dengue; general issues related to FDA and NIH funding; all issues related to the Innovations for Healthier Americans Initiative and the 21st Century Cures Initiative including all provisions of HR6 "To accelerate the discovery, development, and delivery of 21st century cures, and for other purposes (21st Century Cures Act)"; all provisions of Preserving Access to Orphan Drugs Act (discussion draft), HR3678 "Preserving Access to Orphan Drugs Act" and HR3618 "Orphan Drug Fairness Act"; education and awareness of diabetes and related treatments; education about our new cholesterol lowering drug and policy issues related to cardiovascular disease; issues related to barriers to the export of domestically manufactured vaccines; general issues related to the value of prescription medicines; general issues related to the importation of prescription drugs including all progvisions of S122 "Safe and Affordable Drugs from Canada Act of 2015"; issues related to the Over The Counter (OTC) Monograph reform; and general issues related to access to adult vaccines.

Education and awareness of the 2014-2015 influenza season; education and awareness of Avian influenza; education and awareness of pandemic and biodefense funding; education and awareness of Dengue; general issues related to FDA and NIH funding; all provisions of S320 and HR744 "Medical Innovation Act"; the importance of immunizations for herd immunity; all issues related to the 21st Century Cures Initiative including all provisions of HR6 "To accelerate the discovery, development, and delivery of 21st century cures, and for other purposes (21st Century Cures Act)"; general issues related to the importation of pharmaceutical products, including all provisions of S122 "Safe and Affordable Drugs from Canada Act of 2015; all provisions of Preserving Access to Orphan Drugs Act (discussion draft); The President's Budget Proposal - the proposal related to reducing from 12 years to 7 years the data exclusivity period for innovator biologics and the proposal related to generating additional savings from the Independent Payment Advisory Board (IPAB); education and awareness of diabetes and related treatments; issues related to the need for research into clinical tools to diagnose and assess the severity of atopic dermatitis; and education and awareness of cardiovascular disease and related treatments.

Education and awareness of the 2014-2015 influenza season; education and awareness of Avian influenza; education and awareness of pandemic and biodefense funding; education and awareness of Dengue; general issues related to FDA and NIH funding; all issues related to the Innovations for Healthier Americans Initiative and the 21st Century Cures Initiative including all provisions of HR6 "To accelerate the discovery, development, and delivery of 21st century cures, and for other purposes (21st Century Cures Act)"; all provisions of Preserving Access to Orphan Drugs Act (discussion draft); education and awareness of diabetes and related treatments; education about our new cholesterol lowering drug and policy issues related to cardiovascular disease; issues related to barriers to the export of domestically manufactured vaccines; general issues related to the value of prescription medicines; issues related to the Over The Counter (OTC) Monograph reform; general issues related to access to adult vaccines; and all provisions of S1972 "Airline Access to Emergency Epinephrine Act of 2015.".

Education and awareness of the 2014-2015 influenza season; education and awareness of Avian influenza; education and awareness of pandemic and biodefense funding; education and awareness of Dengue; general issues related to FDA and NIH funding; all provisions of S320 and HR744 "Medical Innovation Act"; the importance of immunizations for herd immunity; all issues related to the 21st Century Cures Initiative including all provisions of HR6 "To accelerate the discovery, development, and delivery of 21st century cures, and for other purposes (21st Century Cures Act)"; general issues related to the importation of pharmaceutical products, including all provisions of S122 "Safe and Affordable Drugs from Canada Act of 2015; all provisions of Preserving Access to Orphan Drugs Act (discussion draft); The President's Budget Proposal - the proposal related to reducing from 12 years to 7 years the data exclusivity period for innovator biologics and the proposal related to generating additional savings from the Independent Payment Advisory Board (IPAB); education and awareness of diabetes and related treatments; issues related to the need for research into clinical tools to diagnose and assess the severity of atopic dermatitis; and education and awareness of cardiovascular disease and related treatments.

Education and awareness of the 2014-2015 influenza season; education and awareness of Avian influenza; education and awareness of pandemic and biodefense funding; education and awareness of Dengue; general issues related to FDA and NIH funding; all provisions of S320 and HR744 "Medical Innovation Act"; the importance of immunizations for herd immunity; all issues related to the 21st Century Cures Initiative including all provisions of HR6 "To accelerate the discovery, development, and delivery of 21st century cures, and for other purposes (21st Century Cures Act)"; general issues related to the importation of pharmaceutical products, including all provisions of S122 "Safe and Affordable Drugs from Canada Act of 2015; all provisions of Preserving Access to Orphan Drugs Act (discussion draft); The President's Budget Proposal - the proposal related to reducing from 12 years to 7 years the data exclusivity period for innovator biologics and the proposal related to generating additional savings from the Independent Payment Advisory Board (IPAB); education and awareness of diabetes and related treatments; issues related to the need for research into clinical tools to diagnose and assess the severity of atopic dermatitis; and education and awareness of cardiovascular disease and related treatments.

Education and awareness of the 2014-2015 influenza season; education and awareness of pandemic and biodefense funding; education and awareness of Dengue; general issues related to FDA and NIH funding; all provisions of S320 and HR744 "Medical Innovation Act"; the importance of immunizations for herd immunity; all issues related to the 21st Century Cures Initiative; general issues related to the importation of pharmaceutical products, including all provisions of S122 "Safe and Affordable Drugs from Canada Act of 2015; all provisions of Preserving Access to Orphan Drugs Act (discussion draft); The President's Budget Proposal - the proposal related to reducing from 12 years to 7 years the data exclusivity period for innovator biologics and the proposal related to generating additional savings from the Independent Payment Advisory Board (IPAB); education and awareness of diabetes and related treatments; OTC-HSA; general issues related to awareness of Ebola; and education and awareness of cardiovascular disease and related treatments.

Education and awareness of the 2014-2015 influenza season; education and awareness of Avian influenza; education and awareness of pandemic and biodefense funding; education and awareness of Dengue; general issues related to FDA and NIH funding; all provisions of S320 and HR744 "Medical Innovation Act"; the importance of immunizations for herd immunity; all issues related to the 21st Century Cures Initiative including all provisions of HR6 "To accelerate the discovery, development, and delivery of 21st century cures, and for other purposes (21st Century Cures Act)"; general issues related to the importation of pharmaceutical products, including all provisions of S122 "Safe and Affordable Drugs from Canada Act of 2015; all provisions of Preserving Access to Orphan Drugs Act (discussion draft); The President's Budget Proposal - the proposal related to reducing from 12 years to 7 years the data exclusivity period for innovator biologics and the proposal related to generating additional savings from the Independent Payment Advisory Board (IPAB); education and awareness of diabetes and related treatments; issues related to the need for research into clinical tools to diagnose and assess the severity of atopic dermatitis; and education and awareness of cardiovascular disease and related treatments.

General issues related to corporate tax reform, including the deduction of interest, an extension of bonus depreciation, a delay of the medical device tax, and a strengthened, permanent U.S. R&D tax credit, including all provisions of HR880 "American Research and Competitiveness Act of 2015"; and proposed amendment #2 to the Senate amendment to HR 2029, Rules Committee Print 114-40, showing the text of "Protecting Americans from Tax Hikes Act of 2015"; general issues related to the 40% excise tax on employer-sponsored health care, including all provisions of S2045 and HR2050 "Middle Class Health Benefits Tax Repeal Act", all provisions of HR879 "Ax the Tax on Middle Class Americans' Health Plans Act", and proposed amendment #1 to the Senate amendment to HR2029, Rules Committee Print 114-39, showing the text of the "Consolidated Appropriations Act, 2016"; and all provisions of HR1270 and S709 "Restoring Access to Medication Act of 2015".

Issues related to corporate tax reform, including the deduction of interest and a strengthened and permanent U.S. R&D tax credit, and all provisions of HR880 "American Research and Competitiveness Act of 2015"; all provisions of HR1270 and S709 "Restoring Access to Medication Act of 2015"; general issues related to the 40% excise tax on employer-sponsored health care, including all provisions of S2045 and HR2050 "Middle Class Health Benefits Tax Repeal Act" and all provisions of HR879 "Ax the Tax on Middle Class Americans' Health Plans Act"

Issues related to corporate tax reform, including the deduction of interest, the Orphan drug tax credit, and a strengthened and permanent U.S. R&D tax credit, and all provisions of HR880 "American Research and Competitiveness Act of 2015"; and all provisions of HR1270 and S709 "Restoring Access to Medication Act of 2015"

Corporate tax reform; a strengthened and permanent U.S. R&D tax credit, including all provisions of HR880 "American Research and Competitiveness Act of 2015"; and all provisions of HR1270 and S709 "Restoring Access to Medication Act of 2015"

General issues related to corporate tax reform, including the deduction of interest, an extension of bonus depreciation, a delay of the medical device tax, and a strengthened, permanent U.S. R&D tax credit, including all provisions of HR880 "American Research and Competitiveness Act of 2015"; and proposed amendment #2 to the Senate amendment to HR 2029, Rules Committee Print 114-40, showing the text of "Protecting Americans from Tax Hikes Act of 2015"; general issues related to the 40% excise tax on employer-sponsored health care, including all provisions of S2045 and HR2050 "Middle Class Health Benefits Tax Repeal Act", all provisions of HR879 "Ax the Tax on Middle Class Americans' Health Plans Act", and proposed amendment #1 to the Senate amendment to HR2029, Rules Committee Print 114-39, showing the text of the "Consolidated Appropriations Act, 2016"; and all provisions of HR1270 and S709 "Restoring Access to Medication Act of 2015".

Issues related to corporate tax reform, including the deduction of interest and a strengthened and permanent U.S. R&D tax credit, and all provisions of HR880 "American Research and Competitiveness Act of 2015"; all provisions of HR1270 and S709 "Restoring Access to Medication Act of 2015"; general issues related to the 40% excise tax on employer-sponsored health care, including all provisions of S2045 and HR2050 "Middle Class Health Benefits Tax Repeal Act" and all provisions of HR879 "Ax the Tax on Middle Class Americans' Health Plans Act"

Issues related to corporate tax reform, including the deduction of interest, the Orphan drug tax credit, and a strengthened and permanent U.S. R&D tax credit, and all provisions of HR880 "American Research and Competitiveness Act of 2015"; and all provisions of HR1270 and S709 "Restoring Access to Medication Act of 2015"

International intellectual property issues; general issues related to patent settlements; and all provisions of HR9 "The Innovation Act" and S1137 "Protecting American Talent and Entrepreneurship Act of 2015"

International intellectual property issues; general issues related to patent settlements; and all provisions of HR9 "The Innovation Act" and S1137 "Protecting American Talent and Entrepreneurship Act of 2015"

International intellectual property issues; general issues related to patent settlements; and all provisions of HR9 "The Innovation Act" and S1137 "Protecting American Talent and Entrepreneurship Act of 2015"

Issues related to the Medicaid rebate policy; general issues related to the Mediare Part D Program; coverage and reimbursement for the Medicare Part D prescription drug benefit and all provisions of S31 "Medicare Prescription Drug Price Negotiation Act"; proposals set forth in the President's Budget Request related to restructuring copayments for generic and brand drugs for low income beneficiaries; reducing reimbursement for Medicare Part B medicines; all provisions of HR2 "Medicare Access and CHIP Reauthorization Act of 2015"; all provisions of HR2005 and S1083 "Medicare Drug Savings Act of 2015" and general issues related to chronic care reform in the Medicare program.

Issues related to the Medicaid rebate policy; general issues related to the Mediare Part D Program; coverage and reimbursement for the Medicare Part D prescription drug benefit and all provisions of S31 "Medicare Prescription Drug Price Negotiation Act"; proposals set forth in the President's Budget Request related to restructuring copayments for generic and brand drugs for low income beneficiaries; reducing reimbursement for Medicare Part B medicines; all provisions of HR2 "Medicare Access and CHIP Reauthorization Act of 2015"; all provisions of HR2005 and S1083 "Medicare Drug Savings Act of 2015" and general issues related to chronic care reform in the Medicare program.

International intellectual property issues; general issues related to patent settlements; and all provisions of HR9 "The Innovation Act" and S1137 "Protecting American Talent and Entrepreneurship Act of 2015"

International intellectual property issues; general issues related to patent settlements; and all provisions of HR9 "The Innovation Act" and S1137 "Protecting American Talent and Entrepreneurship Act of 2015"

International intellectual property issues; general issues related to patent settlements; and all provisions of HR9 "The Innovation Act" and S1137 "Protecting American Talent and Entrepreneurship Act of 2015"

Education and awareness of the 2014-2015 influenza season; education and awareness of Avian influenza; education and awareness of pandemic and biodefense funding; education and awareness of Dengue; general issues related to FDA and NIH funding; all provisions of S320 and HR744 "Medical Innovation Act"; the importance of immunizations for herd immunity; all issues related to the 21st Century Cures Initiative including all provisions of HR6 "To accelerate the discovery, development, and delivery of 21st century cures, and for other purposes (21st Century Cures Act)"; general issues related to the importation of pharmaceutical products, including all provisions of S122 "Safe and Affordable Drugs from Canada Act of 2015; all provisions of Preserving Access to Orphan Drugs Act (discussion draft); The President's Budget Proposal - the proposal related to reducing from 12 years to 7 years the data exclusivity period for innovator biologics and the proposal related to generating additional savings from the Independent Payment Advisory Board (IPAB); education and awareness of diabetes and related treatments; issues related to the need for research into clinical tools to diagnose and assess the severity of atopic dermatitis; and education and awareness of cardiovascular disease and related treatments.

Education and awareness of the 2014-2015 influenza season; education and awareness of Avian influenza; education and awareness of pandemic and biodefense funding; education and awareness of Dengue; general issues related to FDA and NIH funding; all provisions of S320 and HR744 "Medical Innovation Act"; the importance of immunizations for herd immunity; all issues related to the 21st Century Cures Initiative including all provisions of HR6 "To accelerate the discovery, development, and delivery of 21st century cures, and for other purposes (21st Century Cures Act)"; general issues related to the importation of pharmaceutical products, including all provisions of S122 "Safe and Affordable Drugs from Canada Act of 2015; all provisions of Preserving Access to Orphan Drugs Act (discussion draft); The President's Budget Proposal - the proposal related to reducing from 12 years to 7 years the data exclusivity period for innovator biologics and the proposal related to generating additional savings from the Independent Payment Advisory Board (IPAB); education and awareness of diabetes and related treatments; issues related to the need for research into clinical tools to diagnose and assess the severity of atopic dermatitis; and education and awareness of cardiovascular disease and related treatments.

Education and awareness of the 2015-2016 influenza season; education and awareness of pandemic and biodefense funding; education and awareness of Dengue; general issues related to FDA and NIH funding; all issues related to the Innovations for Healthier Americans Initiative and the 21st Century Cures Initiative including all provisions of HR6 "To accelerate the discovery, development, and delivery of 21st century cures, and for other purposes (21st Century Cures Act)"; all provisions of Preserving Access to Orphan Drugs Act (discussion draft), HR3678 "Preserving Access to Orphan Drugs Act" and HR3618 "Orphan Drug Fairness Act"; education and awareness of diabetes and related treatments; education about our new cholesterol lowering drug and policy issues related to cardiovascular disease; issues related to barriers to the export of domestically manufactured vaccines; general issues related to the value of prescription medicines; general issues related to the importation of prescription drugs including all progvisions of S122 "Safe and Affordable Drugs from Canada Act of 2015"; issues related to the Over The Counter (OTC) Monograph reform; and general issues related to access to adult vaccines.

Education and awareness of the 2014-2015 influenza season; education and awareness of pandemic and biodefense funding; education and awareness of Dengue; general issues related to FDA and NIH funding; all provisions of S320 and HR744 "Medical Innovation Act"; the importance of immunizations for herd immunity; all issues related to the 21st Century Cures Initiative; general issues related to the importation of pharmaceutical products, including all provisions of S122 "Safe and Affordable Drugs from Canada Act of 2015; all provisions of Preserving Access to Orphan Drugs Act (discussion draft); The President's Budget Proposal - the proposal related to reducing from 12 years to 7 years the data exclusivity period for innovator biologics and the proposal related to generating additional savings from the Independent Payment Advisory Board (IPAB); education and awareness of diabetes and related treatments; OTC-HSA; general issues related to awareness of Ebola; and education and awareness of cardiovascular disease and related treatments.

Education and awareness of the 2014-2015 influenza season; education and awareness of Avian influenza; education and awareness of pandemic and biodefense funding; education and awareness of Dengue; general issues related to FDA and NIH funding; all issues related to the Innovations for Healthier Americans Initiative and the 21st Century Cures Initiative including all provisions of HR6 "To accelerate the discovery, development, and delivery of 21st century cures, and for other purposes (21st Century Cures Act)"; all provisions of Preserving Access to Orphan Drugs Act (discussion draft); education and awareness of diabetes and related treatments; education about our new cholesterol lowering drug and policy issues related to cardiovascular disease; issues related to barriers to the export of domestically manufactured vaccines; general issues related to the value of prescription medicines; issues related to the Over The Counter (OTC) Monograph reform; general issues related to access to adult vaccines; and all provisions of S1972 "Airline Access to Emergency Epinephrine Act of 2015.".

General issues related to corporate tax reform, including the deduction of interest, an extension of bonus depreciation, a delay of the medical device tax, and a strengthened, permanent U.S. R&D tax credit, including all provisions of HR880 "American Research and Competitiveness Act of 2015"; and proposed amendment #2 to the Senate amendment to HR 2029, Rules Committee Print 114-40, showing the text of "Protecting Americans from Tax Hikes Act of 2015"; general issues related to the 40% excise tax on employer-sponsored health care, including all provisions of S2045 and HR2050 "Middle Class Health Benefits Tax Repeal Act", all provisions of HR879 "Ax the Tax on Middle Class Americans' Health Plans Act", and proposed amendment #1 to the Senate amendment to HR2029, Rules Committee Print 114-39, showing the text of the "Consolidated Appropriations Act, 2016"; and all provisions of HR1270 and S709 "Restoring Access to Medication Act of 2015".

Issues related to corporate tax reform, including the deduction of interest and a strengthened and permanent U.S. R&D tax credit, and all provisions of HR880 "American Research and Competitiveness Act of 2015"; all provisions of HR1270 and S709 "Restoring Access to Medication Act of 2015"; general issues related to the 40% excise tax on employer-sponsored health care, including all provisions of S2045 and HR2050 "Middle Class Health Benefits Tax Repeal Act" and all provisions of HR879 "Ax the Tax on Middle Class Americans' Health Plans Act"

Issues related to the Medicaid rebate policy; general issues related to the Medicare Part D program; coverage and reimbursement for the Medicare Part D prescription drug benefit and all provisions of S31 "Medicare Prescription Drug Price Negotiation Act"; general issues related to the Medicare Part B reimbursement of prescription drugs; proposals set forth in the President's Budget Request relating to applying a Medicaid rebate to Medicare Part D for low income subsidy beneficiaries, increasing the manufacturer Part D coverage gap discounts for brand name drugs, repealing the non-interference provision, restructuring generic and brand copayments for low income subsidy beneficiaries, and reducing reimbursement for Medicare Part B medicines; and all provisions of HR2 "Medicare Access and CHIP Reauthorization Act of 2015"

Issues related to the Medicaid prescription drug rebate program policy; general issues related to the Medicare Part D Program; coverage and reimbursement for the Medicare Part D prescription drug benefit and all provisions of S31 "Medicare Prescription Drug Price Negotiation Act".

Issues related to the Medicaid rebate policy; general issues related to the Mediare Part D Program; coverage and reimbursement for the Medicare Part D prescription drug benefit and all provisions of S31 "Medicare Prescription Drug Price Negotiation Act"; proposals set forth in the President's Budget Request related to restructuring copayments for generic and brand drugs for low income beneficiaries; reducing reimbursement for Medicare Part B medicines; all provisions of HR2 "Medicare Access and CHIP Reauthorization Act of 2015"; all provisions of HR2005 and S1083 "Medicare Drug Savings Act of 2015" and general issues related to chronic care reform in the Medicare program.

Issues related to the Medicaid rebate policy; general issues related to the Mediare Part D Program; coverage and reimbursement for the Medicare Part D prescription drug benefit and all provisions of S31 "Medicare Prescription Drug Price Negotiation Act"; and general issues related to chronic care reform in the Medicare program.

Issues related to the Medicaid rebate policy; general issues related to the Mediare Part D Program; coverage and reimbursement for the Medicare Part D prescription drug benefit and all provisions of S31 "Medicare Prescription Drug Price Negotiation Act"; proposals set forth in the President's Budget Request related to restructuring copayments for generic and brand drugs for low income beneficiaries; reducing reimbursement for Medicare Part B medicines; all provisions of HR2 "Medicare Access and CHIP Reauthorization Act of 2015"; all provisions of HR2005 and S1083 "Medicare Drug Savings Act of 2015" and general issues related to chronic care reform in the Medicare program.

Education and awareness of the 2014-2015 influenza season; education and awareness of Avian influenza; education and awareness of pandemic and biodefense funding; education and awareness of Dengue; general issues related to FDA and NIH funding; all provisions of S320 and HR744 "Medical Innovation Act"; the importance of immunizations for herd immunity; all issues related to the 21st Century Cures Initiative including all provisions of HR6 "To accelerate the discovery, development, and delivery of 21st century cures, and for other purposes (21st Century Cures Act)"; general issues related to the importation of pharmaceutical products, including all provisions of S122 "Safe and Affordable Drugs from Canada Act of 2015; all provisions of Preserving Access to Orphan Drugs Act (discussion draft); The President's Budget Proposal - the proposal related to reducing from 12 years to 7 years the data exclusivity period for innovator biologics and the proposal related to generating additional savings from the Independent Payment Advisory Board (IPAB); education and awareness of diabetes and related treatments; issues related to the need for research into clinical tools to diagnose and assess the severity of atopic dermatitis; and education and awareness of cardiovascular disease and related treatments.

Education and awareness of the 2014-2015 influenza season; education and awareness of Avian influenza; education and awareness of pandemic and biodefense funding; education and awareness of Dengue; general issues related to FDA and NIH funding; all provisions of S320 and HR744 "Medical Innovation Act"; the importance of immunizations for herd immunity; all issues related to the 21st Century Cures Initiative including all provisions of HR6 "To accelerate the discovery, development, and delivery of 21st century cures, and for other purposes (21st Century Cures Act)"; general issues related to the importation of pharmaceutical products, including all provisions of S122 "Safe and Affordable Drugs from Canada Act of 2015; all provisions of Preserving Access to Orphan Drugs Act (discussion draft); The President's Budget Proposal - the proposal related to reducing from 12 years to 7 years the data exclusivity period for innovator biologics and the proposal related to generating additional savings from the Independent Payment Advisory Board (IPAB); education and awareness of diabetes and related treatments; issues related to the need for research into clinical tools to diagnose and assess the severity of atopic dermatitis; and education and awareness of cardiovascular disease and related treatments.

Education and awareness of the 2014-2015 influenza season; education and awareness of pandemic and biodefense funding; education and awareness of Dengue; general issues related to FDA and NIH funding; all provisions of S320 and HR744 "Medical Innovation Act"; the importance of immunizations for herd immunity; all issues related to the 21st Century Cures Initiative; general issues related to the importation of pharmaceutical products, including all provisions of S122 "Safe and Affordable Drugs from Canada Act of 2015; all provisions of Preserving Access to Orphan Drugs Act (discussion draft); The President's Budget Proposal - the proposal related to reducing from 12 years to 7 years the data exclusivity period for innovator biologics and the proposal related to generating additional savings from the Independent Payment Advisory Board (IPAB); education and awareness of diabetes and related treatments; OTC-HSA; general issues related to awareness of Ebola; and education and awareness of cardiovascular disease and related treatments.

Issues related to corporate tax reform, including the deduction of interest, the Orphan drug tax credit, and a strengthened and permanent U.S. R&D tax credit, and all provisions of HR880 "American Research and Competitiveness Act of 2015"; and all provisions of HR1270 and S709 "Restoring Access to Medication Act of 2015"

Corporate tax reform; a strengthened and permanent U.S. R&D tax credit, including all provisions of HR880 "American Research and Competitiveness Act of 2015"; and all provisions of HR1270 and S709 "Restoring Access to Medication Act of 2015"

Issues related to corporate tax reform, including the deduction of interest, the Orphan drug tax credit, and a strengthened and permanent U.S. R&D tax credit, and all provisions of HR880 "American Research and Competitiveness Act of 2015"; and all provisions of HR1270 and S709 "Restoring Access to Medication Act of 2015"

General issues related to corporate tax reform, including the deduction of interest, an extension of bonus depreciation, a delay of the medical device tax, and a strengthened, permanent U.S. R&D tax credit, including all provisions of HR880 "American Research and Competitiveness Act of 2015"; and proposed amendment #2 to the Senate amendment to HR 2029, Rules Committee Print 114-40, showing the text of "Protecting Americans from Tax Hikes Act of 2015"; general issues related to the 40% excise tax on employer-sponsored health care, including all provisions of S2045 and HR2050 "Middle Class Health Benefits Tax Repeal Act", all provisions of HR879 "Ax the Tax on Middle Class Americans' Health Plans Act", and proposed amendment #1 to the Senate amendment to HR2029, Rules Committee Print 114-39, showing the text of the "Consolidated Appropriations Act, 2016"; and all provisions of HR1270 and S709 "Restoring Access to Medication Act of 2015".

Issues related to corporate tax reform, including the deduction of interest and a strengthened and permanent U.S. R&D tax credit, and all provisions of HR880 "American Research and Competitiveness Act of 2015"; all provisions of HR1270 and S709 "Restoring Access to Medication Act of 2015"; general issues related to the 40% excise tax on employer-sponsored health care, including all provisions of S2045 and HR2050 "Middle Class Health Benefits Tax Repeal Act" and all provisions of HR879 "Ax the Tax on Middle Class Americans' Health Plans Act"

General issues related to Trade Promotion Authority (TPA) including all such provisions of S995 and HR1890 "Bipartisan Congressional Trade Priorities and Accountability Act of 2015" and HR1314 "Ensuring Tax Exempt Organizations the Right to Appeal Act (or Trade Act of 2015)" and such portions of those bills as included in HR 2146 Defending Public Safety Employees Retirement Act and general issues related to the Trans-Pacific Partnership (TPP) and Transatlantic Trade and Investment Partnership (TTIP) negotiations.

General issues related to Trade Promotion Authority (TPA) including all such provisions of S995 and HR1890 "Bipartisan Congressional Trade Priorities and Accountability Act of 2015" and HR1314 "Ensuring Tax Exempt Organizations the Right to Appeal Act (or Trade Act of 2015)" and such portions of those bills as included in HR 2146 Defending Public Safety Employees Retirement Act and general issues related to the Trans-Pacific Partnership (TPP) and Transatlantic Trade and Investment Partnership (TTIP) negotiations.

General issues related to Trade Promotion Authority (TPA) including all such provisions of S995 and HR1890 "Bipartisan Congressional Trade Priorities and Accountability Act of 2015" and HR1314 "Ensuring Tax Exempt Organizations the Right to Appeal Act (or Trade Act of 2015)" and such portions of those bills as included in HR 2146 Defending Public Safety Employees Retirement Act and general issues related to the Trans-Pacific Partnership (TPP) and Transatlantic Trade and Investment Partnership (TTIP) negotiations.

All provisions of HR 2052 and S 1023 "Global Investment in American Jobs Act of 2013"

All provisions of HR2052 "Global Investment in American Jobs Act of 2013"

All provisions of HR2052 "Global Investment in American Jobs Act of 2013"

Issues related to foreign direct investement in the U.S. including all provisions of HR2052 "Global Investment in American Jobs Act of 2013"

All provisions of HR2052 "Global Investment in American Jobs Act of 2013"

Corporate tax reform; all provisions of HR 4718 "To amend the Internal Revenue Code of 1986 to modify and make permanent bonus depreciation"; a strengthened and permanent U.S. R&D tax credit, including all such provisions in HR 4438 "American Research and Competitiveness Act of 2014", HR 3474 "Hire More Heroes Act of 2014", and HR4 "Jobs for America Act"; S2715 "Competitiveness and Opportunity by Modernizing and Permanently Extending the Tax Credit for Experimentation Act of 2014 orthe COMPETE Act of 2014; tax policy issues related to corporate inversions including S2786 " Corporate Inverters Earnings Stripping Reform Act of 2014" and HR4679 & S2360 "Stop Corporate Inversions Act of 2014" and S2704 & HR5278 "No Federal Contracts for Corporate Deserters Act of 2014"; and all provisions of HR2835 and S 1647 "Restoring Access to Medication Act of 2013"

Corporate tax reform, including Chairman Camps discussion draft legislation Tax Reform Act of 2014; a strengthened and permanent U.S. R&D tax credit; and all provisions of HR 2835 and S1647 "Restoring Access to Medication Act of 2013"

Corporate tax reform; all provisions of HR 4718 "To amend the Internal Revenue Code of 1986 to modify and make permanent bonus depreciation"; a strengthened and permanent U.S. R&D tax credit, including all such provisions in HR 4438 "American Research and Competitiveness Act of 2014", S2715 "Competitiveness and Opportunity by Modernizing and Permanently Extending the Tax Credit for Experimentation Act of 2014 or the COMPETE Act of 2014, and in S2260 "Expiring Provisions Improvement, Reform, andEfficiency Act of 2014 (or EXPIRE Act of 2014); tax policy issues related to corporate inversions including S2786 "Corporate Inverters Earnings Stripping Reform Act of 2014" and HR4679 & S2360 "Stop Corporate Inversions Act of 2014" and S2704 & HR5278 "No Federal Contracts for Corporate Deserters Act of 2014"; and all provisions of HR2835 and S 1647 "Restoring Access to Medication Act of 2013"

Corporate tax reform; all provisions of HR 4718 "To amend the Internal Revenue Code of 1986 to modify and make permanent bonus depreciation"; a strengthened and permanent U.S. R&D tax credit, including all such provisions in HR 4438 "American Research and Competitiveness Act of 2014", HR 3474 "Hire More Heroes Act of 2014", and HR4 "Jobs for America Act"; S2715 "Competitiveness and Opportunity by Modernizing and Permanently Extending the Tax Credit for Experimentation Act of 2014 or the COMPETE Act of 2014; tax policy issues related to corporate inversions including S2786 " Corporate Inverters Earnings Stripping Reform Act of 2014" and HR4679 & S2360 "Stop Corporate Inversions Act of 2014" and S2704 & HR5278 "No Federal Contracts for Corporate Deserters Act of 2014"; and all provisions of HR2835 and S 1647 "Restoring Access to Medication Act of 2013"

Corporate tax reform, including Chairman Camp's discussion draft legislation "Tax Reform Act of 2014"; all provisions of HR 4718 "To amend the Internal Revenue Code of 1986 to modify and make permanent bonus depreciation"; and maintaining the orphan drug tax credit; a strengthened and permanent U.S. R&D tax credit, including all such provisions in HR 4438 "American Research and Competitiveness Act of 2014" and HR 3474 "Hire More Heroes Act of 2014"; and all provisions of HR2835 and S 1647 "RestoringAccess to Medication Act of 2013"

Corporate tax reform; all provisions of HR 4718 "To amend the Internal Revenue Code of 1986 to modify and make permanent bonus depreciation"; a strengthened and permanent U.S. R&D tax credit, including all such provisions in HR 4438 "American Research and Competitiveness Act of 2014", S2715 "Competitiveness and Opportunity by Modernizing and Permanently Extending the Tax Credit for Experimentation Act of 2014 or the COMPETE Act of 2014, and in S2260 "Expiring Provisions Improvement, Reform, andEfficiency Act of 2014 (or EXPIRE Act of 2014); tax policy issues related to corporate inversions including S2786 "Corporate Inverters Earnings Stripping Reform Act of 2014" and HR4679 & S2360 "Stop Corporate Inversions Act of 2014" and S2704 & HR5278 "No Federal Contracts for Corporate Deserters Act of 2014"; and all provisions of HR2835 and S 1647 "Restoring Access to Medication Act of 2013"

Corporate tax reform; all provisions of HR 4718 "To amend the Internal Revenue Code of 1986 to modify and make permanent bonus depreciation"; a strengthened and permanent U.S. R&D tax credit, including all such provisions in HR 4438 "American Research and Competitiveness Act of 2014", HR 3474 "Hire More Heroes Act of 2014", and HR4 "Jobs for America Act"; S2715 "Competitiveness and Opportunity by Modernizing and Permanently Extending the Tax Credit for Experimentation Act of 2014 orthe COMPETE Act of 2014; tax policy issues related to corporate inversions including S2786 " Corporate Inverters Earnings Stripping Reform Act of 2014" and HR4679 & S2360 "Stop Corporate Inversions Act of 2014" and S2704 & HR5278 "No Federal Contracts for Corporate Deserters Act of 2014"; and all provisions of HR2835 and S 1647 "Restoring Access to Medication Act of 2013"

Corporate tax reform; all provisions of HR 4718 "To amend the Internal Revenue Code of 1986 to modify and make permanent bonus depreciation"; a strengthened and permanent U.S. R&D tax credit, including all such provisions in HR 4438 "American Research and Competitiveness Act of 2014", HR 3474 "Hire More Heroes Act of 2014", and HR4 "Jobs for America Act"; S2715 "Competitiveness and Opportunity by Modernizing and Permanently Extending the Tax Credit for Experimentation Act of 2014 or the COMPETE Act of 2014; tax policy issues related to corporate inversions including S2786 " Corporate Inverters Earnings Stripping Reform Act of 2014" and HR4679 & S2360 "Stop Corporate Inversions Act of 2014" and S2704 & HR5278 "No Federal Contracts for Corporate Deserters Act of 2014"; and all provisions of HR2835 and S 1647 "Restoring Access to Medication Act of 2013"

Corporate tax reform, including Chairman Camp's discussion draft legislation "Tax Reform Act of 2014"; all provisions of HR 4718 "To amend the Internal Revenue Code of 1986 to modify and make permanent bonus depreciation"; and maintaining the orphan drug tax credit; a strengthened and permanent U.S. R&D tax credit, including all such provisions in HR 4438 "American Research and Competitiveness Act of 2014" and HR 3474 "Hire More Heroes Act of 2014"; and all provisions of HR2835 and S 1647 "RestoringAccess to Medication Act of 2013"

Corporate tax reform; all provisions of HR 4718 "To amend the Internal Revenue Code of 1986 to modify and make permanent bonus depreciation"; a strengthened and permanent U.S. R&D tax credit, including all such provisions in HR 4438 "American Research and Competitiveness Act of 2014", HR 3474 "Hire More Heroes Act of 2014", and HR4 "Jobs for America Act"; S2715 "Competitiveness and Opportunity by Modernizing and Permanently Extending the Tax Credit for Experimentation Act of 2014 orthe COMPETE Act of 2014; tax policy issues related to corporate inversions including S2786 " Corporate Inverters Earnings Stripping Reform Act of 2014" and HR4679 & S2360 "Stop Corporate Inversions Act of 2014" and S2704 & HR5278 "No Federal Contracts for Corporate Deserters Act of 2014"; and all provisions of HR2835 and S 1647 "Restoring Access to Medication Act of 2013"

Corporate tax reform; all provisions of HR 4718 "To amend the Internal Revenue Code of 1986 to modify and make permanent bonus depreciation"; a strengthened and permanent U.S. R&D tax credit, including all such provisions in HR 4438 "American Research and Competitiveness Act of 2014", HR 3474 "Hire More Heroes Act of 2014", and HR4 "Jobs for America Act"; S2715 "Competitiveness and Opportunity by Modernizing and Permanently Extending the Tax Credit for Experimentation Act of 2014 or the COMPETE Act of 2014; tax policy issues related to corporate inversions including S2786 " Corporate Inverters Earnings Stripping Reform Act of 2014" and HR4679 & S2360 "Stop Corporate Inversions Act of 2014" and S2704 & HR5278 "No Federal Contracts for Corporate Deserters Act of 2014"; and all provisions of HR2835 and S 1647 "Restoring Access to Medication Act of 2013"

Corporate tax reform; all provisions of HR 4718 "To amend the Internal Revenue Code of 1986 to modify and make permanent bonus depreciation"; a strengthened and permanent U.S. R&D tax credit, including all such provisions in HR 4438 "American Research and Competitiveness Act of 2014", S2715 "Competitiveness and Opportunity by Modernizing and Permanently Extending the Tax Credit for Experimentation Act of 2014 or the COMPETE Act of 2014, and in S2260 "Expiring Provisions Improvement, Reform, andEfficiency Act of 2014 (or EXPIRE Act of 2014); tax policy issues related to corporate inversions including S2786 "Corporate Inverters Earnings Stripping Reform Act of 2014" and HR4679 & S2360 "Stop Corporate Inversions Act of 2014" and S2704 & HR5278 "No Federal Contracts for Corporate Deserters Act of 2014"; and all provisions of HR2835 and S 1647 "Restoring Access to Medication Act of 2013"

Corporate tax reform; all provisions of HR 4718 "To amend the Internal Revenue Code of 1986 to modify and make permanent bonus depreciation"; a strengthened and permanent U.S. R&D tax credit, including all such provisions in HR 4438 "American Research and Competitiveness Act of 2014", S2715 "Competitiveness and Opportunity by Modernizing and Permanently Extending the Tax Credit for Experimentation Act of 2014 or the COMPETE Act of 2014, and in S2260 "Expiring Provisions Improvement, Reform, andEfficiency Act of 2014 (or EXPIRE Act of 2014); tax policy issues related to corporate inversions including S2786 "Corporate Inverters Earnings Stripping Reform Act of 2014" and HR4679 & S2360 "Stop Corporate Inversions Act of 2014" and S2704 & HR5278 "No Federal Contracts for Corporate Deserters Act of 2014"; and all provisions of HR2835 and S 1647 "Restoring Access to Medication Act of 2013"

Corporate tax reform; all provisions of HR 4718 "To amend the Internal Revenue Code of 1986 to modify and make permanent bonus depreciation"; a strengthened and permanent U.S. R&D tax credit, including all such provisions in HR 4438 "American Research and Competitiveness Act of 2014", HR 3474 "Hire More Heroes Act of 2014", and HR4 "Jobs for America Act"; S2715 "Competitiveness and Opportunity by Modernizing and Permanently Extending the Tax Credit for Experimentation Act of 2014 orthe COMPETE Act of 2014; tax policy issues related to corporate inversions including S2786 " Corporate Inverters Earnings Stripping Reform Act of 2014" and HR4679 & S2360 "Stop Corporate Inversions Act of 2014" and S2704 & HR5278 "No Federal Contracts for Corporate Deserters Act of 2014"; and all provisions of HR2835 and S 1647 "Restoring Access to Medication Act of 2013"

Corporate tax reform, including Chairman Camp's discussion draft legislation "Tax Reform Act of 2014"; all provisions of HR 4718 "To amend the Internal Revenue Code of 1986 to modify and make permanent bonus depreciation"; and maintaining the orphan drug tax credit; a strengthened and permanent U.S. R&D tax credit, including all such provisions in HR 4438 "American Research and Competitiveness Act of 2014" and HR 3474 "Hire More Heroes Act of 2014"; and all provisions of HR2835 and S 1647 "RestoringAccess to Medication Act of 2013"

Corporate tax reform; all provisions of HR 4718 "To amend the Internal Revenue Code of 1986 to modify and make permanent bonus depreciation"; a strengthened and permanent U.S. R&D tax credit, including all such provisions in HR 4438 "American Research and Competitiveness Act of 2014", HR 3474 "Hire More Heroes Act of 2014", and HR4 "Jobs for America Act"; S2715 "Competitiveness and Opportunity by Modernizing and Permanently Extending the Tax Credit for Experimentation Act of 2014 or the COMPETE Act of 2014; tax policy issues related to corporate inversions including S2786 " Corporate Inverters Earnings Stripping Reform Act of 2014" and HR4679 & S2360 "Stop Corporate Inversions Act of 2014" and S2704 & HR5278 "No Federal Contracts for Corporate Deserters Act of 2014"; and all provisions of HR2835 and S 1647 "Restoring Access to Medication Act of 2013"

Corporate tax reform; all provisions of HR 4718 "To amend the Internal Revenue Code of 1986 to modify and make permanent bonus depreciation"; a strengthened and permanent U.S. R&D tax credit, including all such provisions in HR 4438 "American Research and Competitiveness Act of 2014", HR 3474 "Hire More Heroes Act of 2014", and HR4 "Jobs for America Act"; S2715 "Competitiveness and Opportunity by Modernizing and Permanently Extending the Tax Credit for Experimentation Act of 2014 orthe COMPETE Act of 2014; tax policy issues related to corporate inversions including S2786 " Corporate Inverters Earnings Stripping Reform Act of 2014" and HR4679 & S2360 "Stop Corporate Inversions Act of 2014" and S2704 & HR5278 "No Federal Contracts for Corporate Deserters Act of 2014"; and all provisions of HR2835 and S 1647 "Restoring Access to Medication Act of 2013"

Corporate tax reform; all provisions of HR 4718 "To amend the Internal Revenue Code of 1986 to modify and make permanent bonus depreciation"; a strengthened and permanent U.S. R&D tax credit, including all such provisions in HR 4438 "American Research and Competitiveness Act of 2014", S2715 "Competitiveness and Opportunity by Modernizing and Permanently Extending the Tax Credit for Experimentation Act of 2014 or the COMPETE Act of 2014, and in S2260 "Expiring Provisions Improvement, Reform, andEfficiency Act of 2014 (or EXPIRE Act of 2014); tax policy issues related to corporate inversions including S2786 "Corporate Inverters Earnings Stripping Reform Act of 2014" and HR4679 & S2360 "Stop Corporate Inversions Act of 2014" and S2704 & HR5278 "No Federal Contracts for Corporate Deserters Act of 2014"; and all provisions of HR2835 and S 1647 "Restoring Access to Medication Act of 2013"

Corporate tax reform; all provisions of HR 4718 "To amend the Internal Revenue Code of 1986 to modify and make permanent bonus depreciation"; a strengthened and permanent U.S. R&D tax credit, including all such provisions in HR 4438 "American Research and Competitiveness Act of 2014", HR 3474 "Hire More Heroes Act of 2014", and HR4 "Jobs for America Act"; S2715 "Competitiveness and Opportunity by Modernizing and Permanently Extending the Tax Credit for Experimentation Act of 2014 or the COMPETE Act of 2014; tax policy issues related to corporate inversions including S2786 " Corporate Inverters Earnings Stripping Reform Act of 2014" and HR4679 & S2360 "Stop Corporate Inversions Act of 2014" and S2704 & HR5278 "No Federal Contracts for Corporate Deserters Act of 2014"; and all provisions of HR2835 and S 1647 "Restoring Access to Medication Act of 2013"

All provisions of HR 2052 and S 1023 "Global Investment in American Jobs Act of 2013"

Corporate tax reform, including Chairman Camps discussion draft legislation Tax Reform Act of 2014; a strengthened and permanent U.S. R&D tax credit; and all provisions of HR 2835 and S1647 "Restoring Access to Medication Act of 2013"